Cadre Holdings, Inc. (CDRE) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.86%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.86% | Share-based compensation / revenue. Period ending 2026-06-30. $12.73M ÷ $685.65M × 100 ≈ 1.86% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 685.65M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 12.73M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 69.07M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $685.65M | $12.73M | $69.07M | (m) | (m) | 1.86% | (m) | (m) |
| 2026-03-31 | (m) | $635.63M | $12.20M | $61.29M | (m) | (m) | 1.92% | (m) | (m) |
| 2025-12-31 | $11.40M | $610.31M | $12.24M | $67.35M | (m) | 1.87% | 2.01% | (m) | (m) |
| 2025-09-30 | (m) | $619.07M | $8.95M | $76.31M | (m) | (m) | 1.45% | (m) | (m) |
| 2025-06-30 | (m) | $572.61M | $8.61M | $63.07M | (m) | (m) | 1.50% | (m) | (m) |
| 2025-03-31 | (m) | $559.81M | $8.27M | $68.33M | (m) | (m) | 1.48% | (m) | (m) |
| 2024-12-31 | $8.38M | $567.56M | $8.37M | $66.76M | (m) | 1.48% | 1.47% | (m) | (m) |
| 2024-09-30 | (m) | $516.16M | $8.56M | $50.03M | (m) | (m) | 1.66% | (m) | (m) |
| 2024-06-30 | (m) | $531.87M | $8.67M | $61.34M | (m) | (m) | 1.63% | (m) | (m) |
| 2024-03-31 | (m) | $508.64M | $8.69M | $57.28M | $4.53M | (m) | 1.71% | 12.65× | Reported |
| 2023-12-31 | $6.95M | $482.53M | $9.37M | $56.52M | $4.53M | 1.44% | 1.94% | 12.47× | Reported |
| 2023-09-30 | (m) | $481.59M | $9.93M | $56.56M | $5.44M | (m) | 2.06% | 10.40× | Reported |
| 2023-06-30 | (m) | $468.03M | $10.38M | $50.15M | $5.93M | (m) | 2.22% | 8.46× | Reported |
| 2023-03-31 | (m) | $465.18M | $11.02M | $42.42M | $6.36M | (m) | 2.37% | 6.67× | Reported |
| 2022-12-31 | $7.09M | $457.84M | $31.86M | $16.72M | $6.21M | 1.55% | 6.96% | 2.69× | Reported |
| 2022-09-30 | (m) | $437.73M | (m) | $13.31M | $6.79M | (m) | (m) | 1.96× | Reported |
| 2022-06-30 | (m) | $424.83M | (m) | $14.54M | $8.69M | (m) | (m) | 1.67× | Reported |
| 2022-03-31 | (m) | $421.16M | (m) | $21.80M | $12.87M | (m) | (m) | 1.69× | Reported |
| 2021-12-31 | $6.46M | $427.29M | $355.00K | $51.72M | $16.43M | 1.51% | 0.08% | 3.15× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $5.63M | $404.64M | (m) | $49.80M | $24.39M | 1.39% | (m) | 2.04× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |
| Conexeu Sciences Inc. (CNXU) | United States | $0.111B | |
| NutriBand Inc. (NTRB) | United States | $0.109B | |
| LAKELAND INDUSTRIES INC (LAKE) | United States | $0.104B | -4.21 |
| Safe Pro Group Inc. (SPAI) | United States | $0.090B | |
| MYOMO, INC. (MYO) | United States | $0.065B | -2.85 |